Assessment of the therapeutic effect of the drug Molixan in the treatment of Syrian hamsters experimentally infected with the SARS-CoV-2 virus

Background. Studying the characteristics of the course of coronavirus infection caused by SARS-CoV-2 remains relevant due to the high mutagenicity of the virus and the prevalence of the disease in the world. The search for new drugs to eliminate clinical manifestations of COVID-19, as well as against its agent, is essential. During the pandemic caused by SARS-CoV-2, dexamethasone was recognized as the only effective anti-inflammatory drug for the treatment of patients with severe form of the disease, but its use leads to a large number of side effects.

The aim. To study the therapeutic effect of the drug Molixan in the treatment of coronavirus infection in model animals – Syrian hamsters.

Methods. To assess the effectiveness of the drug Molixan, we carried out a visual assessment of the condition of the lungs using light microscopy and the morphometry of the lung tissue of experimentally infected Syrian hamsters on the day 6 after infection under different Molixan treatment regimens and during dexamethasone therapy. The test drug was administered using three different doses (22.2 mg/kg, 44.4 mg/kg and 88.8 mg/kg, which are equivalent to doses of 3 mg/kg, 6 mg/kg and 12 mg/kg of human body weight) once daily or dividing the dose into two within 12 h interval in case of multiple (5 days) intramuscular administration. Dexamethasone (comparison drug) was administered at a dose of 20 mg/kg once daily for 5 days.

Results. The studies showed statistically significant effectiveness of using Molixan at a dose of 44.4 mg/kg, divided into two doses, during 5 days. When compared with untreated hamsters, this treatment regimen reduces the degree of generalization and severity of the inflammatory process in the lungs; and the pathomorphological picture is similar to that observed during treatment with Dexamethasone.

Conclusion. The studied drug Molixan is effective as an anti-inflammatory drug in the treatment of the disease caused by SARS-CoV-2.

1. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: Pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020; 39(7): 2085-2094. doi: 10.1007/s10067-020-05190-5

2. Kim JS, Lee JL, Yang JW, Lee KH, Effenberger M, Szpirt W, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021; 11(1): 316. doi: 10.7150/thno.49713

3. Kumar R, Gupta N, Kodan P, Mittal A, Soneja M, Wig N. Battling COVID-19: Using old weapons for a new enemy. Trop Dis Travel Med Vaccines. 2020; 6(1): 6. doi: 10.1186/s40794-020-00107-1

4. Atluri K, Aimlin I, Arora S. Current effective therapeutics in management of COVID-19. J Clin Med. 2022; 11(13): 3838. doi: 10.3390/jcm11133838

5. Salem MA. A response to the recommendations for using dexamethasone for the treatment of COVID-19: The dark side of dexamethasone. J Pharm Pract. 2021; 34(2): 179-180. doi: 10.1177/0897190020979608

6. Andreakos E, Papadaki M, Serhan CN. Dexamethasone, pro‐resolving lipid mediators and resolution of inflammation in COVID‐19. Allergy. 2021; 76(3): 626. doi: 10.1111/all.14595

7. Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al. COVID-19 infection and glucocorticoids: Update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020; 43: 1141-1147. doi: 10.1007/s40618-020-01266-w

8. Oray M, Samra KA, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15(4): 457-465. doi: 10.1517/14740338.2016.1140743

9. Golofeevsky VYu, Antushevich AE, Antonov VG, Grebenyuk AA. New model of experimental cirrhosis for estimation of hepatoprotective and antifibrotic efficiency of drugs. Experimental and Clinical Gastroenterology. 2017; 10(146): 88-93. (In Russ.).

10. Horowitz RI, Freeman PR, Bruzzese J. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases. Respir Med Case Rep. 2020; 30: 101063. doi: 10.1016/j.rmcr.2020.101063

11. Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, Lee AC, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: Implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020; 71(9): 2428-2446. doi: 10.1093/cid/ciaa325

12. Vasiliev AN, Gavrishina EV, Niyazov RR, Adonin VK, Tuter EA, Bunyatyan ND, et al. Analysis of foreign and domestic scientific and methodological approaches to choice of comparator drug in preclinical and clinical studies. International Journal of Applied and Fundamental Research. 2015; 10(4): 671-673. (In Russ.). URL: https://applied-research.ru/ru/article/view?id=7603 [дата доступа: 04.03.2024].

13. Brocato RL, Hammerbeck CD, Bell TM, Wells JB, Queen LA, Hooper JW. A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus. J Virol. 2014; 88(2): 811-819. doi: 10.1128/jVI.02906-13

14. Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, García-Couce J, et al. Dexamethasone: Insights into pharmacological aspects, therapeutic mechanisms, and delivery systems. ACS Biomater Sci Eng. 2022; 8(5): 1763-1790. doi: 10.1021/acsbiomaterials.2c00026

15. Maskin LP, Bonelli I, Palizas F, Velo AE, Lurbet MF, et al. Highversus low-dose dexamethasone for the treatment of COVID19-related acute respiratory distress syndrome: A multicenter, randomized open-label clinical trial. J Intensive Care Med. 2022; 37(4): 491-499. doi: 10.1177/08850666211066799

16. Yuan L, Zhou M, Ma J, Liu X, Chen P, Zhu H, et al. Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters. Cell Mol Immunol. 2022; 19(2): 290-292. doi: 10.1038/s41423-021-00793-7

17. Dubina MV, Gomonova VV, Taraskina AE, Vasilyeva NV, Sayganov SA. Pathogenesis-based preexposure prophylaxis associated with a low risk of SARS-CoV-2 infection in healthcare workers at a designated COVID-19 hospital: A pilot study. BMC Infect Dis. 2021; 21(1): 536. doi: 10.1186/s12879021-06241-1